December 29, 2014 11:42 AM ET

Pharmaceuticals

Company Overview of MedImmune Vaccines, Inc.

Executive Profile

Bernard Roizman Sc.D.

Director and Member - Scientific Advisory Board, MedImmune Vaccines, Inc.
AgeTotal Calculated CompensationThis person is connected to 1 Board Members in 1 different organizations across 1 different industries.

See Board Relationships
85--

Background

Dr. Bernard Roizman Sc.D. has been a Member of Board of Directors of MedImmune Vaccines, Inc. since 1992. Dr. Roizman has been the Joseph Regenstein Distinguished Service Professor of Virology at the University of Chicago since 1984. He holds B.A. and M.S. degrees from Temple University and an Sc.D. from The Johns Hopkins University. Dr. Roizman is also a member of MedImmune Vaccines, Inc.'s Scientific Advisory Board.

Corporate Headquarters

297 North Bernardo Avenue
Mountain View, California 94043

United States

Phone: 650-919-6500
Fax: 650-919-6611

Board Members Memberships

1992-Present
Director and Member - Scientific Advisory Board

Education

ScD
Johns Hopkins University
MS
Temple University
BA
Temple University

Other Affiliations

Annual Compensation

There is no Annual Compensation data available.

Stocks Options

There is no Stock Options data available.

Total Compensation

There is no Total Compensation data available.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

COMPETITOR COMPENSATION

There is no Competitor Compensation data available.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MedImmune Vaccines, Inc., please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.